Patent Cliff and the Future of Generics in Asia

Trends that will Impact the Market in the Short Term

Regular Price: USD 2,450

Special Price USD 2,205

10% OFF

* Required Fields

Regular Price: USD 2,450

Special Price USD 2,205

PAY BY INVOICE

Be the first to review this product

The global generics industry is in an interesting phase. Prescription volumes for generics are rising in the US and European markets, while regional manufacturers are struggling to meet demand. However, while Asian prescription volumes are lower than that of Western markets, Asian manufacturers are catering to domestic markets and exporting a significant percentage of products to the US and Europe. India, China, South Korea, and Japan are the important Asian markets. The generics industry has moved on after patent cliff, and is more focused on increasing product quality and market share. Overall, the global generics market will see an average growth in the next 2-3 years.

Table of Contents

Executive SummaryExecutive SummaryExecutive Summary (continued)Executive Summary (continued)Executive Summary (continued)Executive Summary (continued)Key Questions This Study Will AnswerResearch Process and MethodologyPatent Cliff and Global Generics MarketWhat Will The Global Generics Market Look Like in 2015?What Can We Expect in the Next Three Years?Opportunities by Therapeutic Segments—Cardiovascular Disease Remains the Most Attractive Segment till 2018 Opportunities by Product Segments—Biologics or Oral Solids?With Less Molecules To Lose Exclusivity, Will the Generics Industry Continue To Grow?Major Losses Due To Patent Cliff in 2014Selected Patent Expiries in 2015Who Gets the Maximum Advantage Post Loss of Exclusivity (LOE) of Major Drugs?Challenges for Drug ManufacturersMajor Models and Trends Post 2012 LOE Generics Market in AsiaActivities in the Asian Generics MarketMajor Approvals and New Products in Asia-Pacific Generics Market in 2014 Indian Generics Market Indian Generics Market (continued)Indian Market is Mix of Branded Generics and Un-branded GenericsUniversal Health Coverage Scheme 2015–2019Universal Health Coverage in India and its ImplicationsTo Meet The Demands of Domestic Markets, Generic Manufacturers Have to Produce a SurplusMarkets Other than India to be Equally Lucrative for Generic ManufacturersChinaChinese Generics Market in 2014Generics Market Boom Likely in the Next 3 YearsJapanLOE Scenario in Japanese Pharma Industry 2014–2015Japanese Generics Market in 2014Key Focus of Japanese Pharma Industry—“Quality”The Philippines Indonesia Taiwan and MalaysiaRest of AsiaStrategic RecommendationsIndia, Indonesia, Vietnam, and China to lead APACStrategiesFirst-mover Advantage: Case Study—CymbaltaThe Last WordLegal DisclaimerThe Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition—Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.